IDSA : View All Antimicrobial Resistance for Public Policy

Help Win Congress’s Support for New Antibiotics

Legislative Action Alert: We need your help urging Congress to provide a new FDA approval pathway to help companies bring to market the most urgently needed new antibiotics. Contact Congress today.

New Antibiotic Approval Pathway Would Address Critical Need (PDF)

The Society’s proposed Limited Population Antibacterial Drug (LPAD) mechanism would streamline the development of antibiotics needed to treat the most serious infections.

IDSA Policy: Antimicrobial Resistance

IDSA is working on several fronts to counter “bad bugs” including by promoting development of new drugs, eliminating inappropriate use of antibiotics in agriculture, promoting antimicrobial stewardship programs, and strengthening the U.S. response through surveillance, prevention and control, and research efforts.

Facts about Antibiotic Resistance

The incidence of antibiotic-resistance has been rapidly increasing. At the same time, fewer new antibiotics are being developed.

Patient Stories

Many patients and their families have suffered the debilitating effects of drug-resistant infections.IDSA believes it is important to tell their stories to spur the development of new treatments and to strengthen efforts to control drug resistance. If you would like to share your story, please contact John Heys at jheys@idsociety.org.

View all Antimicrobial Resistance Content for Public Policy

Help Win Congress’s Support for New Antibiotics

New Antibiotic Approval Pathway Would Address Critical Need (PDF)

IDSA Policy: Antimicrobial Resistance

Facts about Antibiotic Resistance

Patient Stories

Infectious Diseases Society of America